| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Mogroside III-A1 targets metabolic and inflammatory pathways. Like other mogrosides, it exhibits antioxidant, antidiabetic, and anticancer activities. Its mechanism of action is believed to involve the modulation of AMPK and other metabolic regulators, similar to its aglycone, Mogrol. As a class, mogrosides are reported to possess these activities.
|
|---|---|
| ln Vitro |
In vitro, Mogroside III-A1 demonstrates biological activity consistent with the mogroside class. It exhibits antioxidant, antidiabetic, and anticancer properties. It contributes to the overall bioactivity of monk fruit extracts. Its sweetening properties make it a valuable compound for research into sweet taste and metabolism.
|
| ln Vivo |
In vivo, Mogroside III-A1 is believed to contribute to the overall health benefits of monk fruit. Its antidiabetic and antioxidant effects are thought to be relevant for metabolic health. As a component of monk fruit extracts, it may play a role in the observed benefits of these extracts in animal models of diabetes and obesity. Specific standalone in vivo data are limited.
|
| Enzyme Assay |
The in vitro antioxidant assay for Mogroside III-A1 involves measuring its ability to scavenge free radicals, such as DPPH or ABTS. The compound is incubated with the radical, and the decrease in absorbance is measured. For antidiabetic activity, its effect on glucose uptake in skeletal muscle cells or its ability to inhibit α-glucosidase can be measured.
|
| Cell Assay |
In vitro cell culture studies for Mogroside III-A1 utilize various cell lines to study its bioactivity. Its anticancer activity is assessed in cancer cell lines using MTT assays. Its anti-inflammatory effects can be studied in macrophage cell lines by measuring cytokine production. Its effect on glucose metabolism can be studied in skeletal muscle or liver cells.
|
| Animal Protocol |
In vivo animal experiments for Mogroside III-A1 are not extensively documented. However, its effects on glucose homeostasis could be studied in rodent models of type 2 diabetes. The compound would be administered orally, and its effect on blood glucose levels would be measured in an oral glucose tolerance test (OGTT). Its anti-inflammatory effects could be studied in models of acute inflammation.
|
| ADME/Pharmacokinetics |
Mogroside III-A1 has a molecular formula of C48H82O19 and a molecular weight of approximately 963 g/mol. It is a solid compound that is soluble in water and organic solvents like DMSO. As a glycoside, it is more polar than its aglycone. It is typically stored as a powder at -20°C for long-term stability. Its stability is maintained under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
Toxicological data for Mogroside III-A1 are limited, as it is a research compound. As a natural component of monk fruit, it is generally recognized as safe for human consumption at dietary levels. However, as a research compound, it is not intended for therapeutic use, and comprehensive toxicity studies are not available. Standard safety precautions should be followed.
|
| References | |
| Additional Infomation |
Mogroside MIII-A1 is a mogroside and also a β-D-glucoside. It is a plant metabolite and is functionally related to mogroside IIA.
Mogroside III-A1 is a research compound with no clinical approval. It is a valuable tool for studying the pharmacology of mogrosides and their potential applications in metabolic diseases. Its bioactivity makes it a compound of interest for research into diabetes, obesity, and the development of functional foods. |
| Molecular Formula |
C48H82O19
|
|---|---|
| Molecular Weight |
963.1533
|
| Exact Mass |
962.545
|
| CAS # |
88901-42-2
|
| PubChem CID |
125126167
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
1059.6±65.0 °C at 760 mmHg
|
| Flash Point |
594.6±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.619
|
| LogP |
1.18
|
| Hydrogen Bond Donor Count |
13
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
67
|
| Complexity |
1720
|
| Defined Atom Stereocenter Count |
25
|
| SMILES |
C[C@H](CC[C@H](C(C)(C)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)[C@H]4CC[C@@]5([C@@]4(C[C@H]([C@@]6([C@H]5CC=C7[C@H]6CC[C@@H](C7(C)C)O)C)O)C)C
|
| InChi Key |
DDDXYRAMQRKPDO-GOILQDHQSA-N
|
| InChi Code |
InChI=1S/C48H82O19/c1-21(22-15-16-46(6)28-12-10-23-24(11-13-29(51)44(23,2)3)48(28,8)30(52)17-47(22,46)7)9-14-31(45(4,5)61)66-43-40(67-42-39(60)36(57)33(54)26(19-50)64-42)37(58)34(55)27(65-43)20-62-41-38(59)35(56)32(53)25(18-49)63-41/h10,21-22,24-43,49-61H,9,11-20H2,1-8H3/t21-,22-,24-,25-,26-,27-,28+,29+,30-,31-,32-,33-,34-,35+,36+,37+,38-,39-,40-,41-,42+,43+,46+,47-,48+/m1/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[[(2R,3S,4S,5R,6S)-6-[(3R,6R)-6-[(3S,8S,9R,10R,11R,13R,14S,17R)-3,11-dihydroxy-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-hydroxy-2-methylheptan-3-yl]oxy-3,4-dihydroxy-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~103.83 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0383 mL | 5.1913 mL | 10.3826 mL | |
| 5 mM | 0.2077 mL | 1.0383 mL | 2.0765 mL | |
| 10 mM | 0.1038 mL | 0.5191 mL | 1.0383 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
